STOCK TITAN

Shockwave Medical, Inc. - $SWAV STOCK NEWS

Welcome to our dedicated page for Shockwave Medical news (Ticker: $SWAV), a resource for investors and traders seeking the latest updates and insights on Shockwave Medical stock.

Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect Shockwave Medical's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.

Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of Shockwave Medical's position in the market.

Rhea-AI Summary
Shockwave Medical's CFO, Dan Puckett, plans to retire in Q1 2024. The company is searching for a successor. Puckett will continue as CFO until then. Puckett's efforts contributed to successful funding rounds and a successful IPO. No concrete positive or negative impacts on stock price.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-5.68%
Tags
none
-
Rhea-AI Summary
Shockwave Medical to participate in investor conferences
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.47%
Tags
conferences
-
Rhea-AI Summary
Shockwave Medical, Inc. announced the pricing of its offering of $650.0 million aggregate principal amount of 1.00% Convertible Senior Notes due 2028. The offering size was increased from $500.0 million. The sale is expected to close on August 15, 2023. The notes will bear interest at a rate of 1.00% per year and will mature on August 15, 2028. Shockwave Medical estimates that the net proceeds from the offering will be approximately $632.9 million.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.31%
Tags
Rhea-AI Summary
SWAV: Shockwave Medical, Inc. Announces $500.0 Million Offering of Convertible Senior Notes due 2028. The notes will be senior, unsecured obligations, convertible under certain conditions. The offering will be used to pay for capped call transactions and for general corporate purposes.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-3.26%
Tags
-
Rhea-AI Summary
Shockwave Medical reports Q2 2023 revenue of $180.2 million, a 49% increase from the same period in 2022. The company announced the availability of the Shockwave C2+ Coronary Intravascular Lithotripsy Catheter in select international markets. They also initiated enrollment in EMPOWER CAD, a study of percutaneous coronary intervention in female patients. The acquisition of Neovasc was closed and integration into Shockwave has begun.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-10.51%
Tags
-
Rhea-AI Summary
Shockwave Medical, Inc. announced that the Centers for Medicare & Medicaid Services (CMS) has created new Medicare Severity Diagnosis Related Group (MS-DRG) codes and payments for coronary Intravascular Lithotripsy (IVL) in the hospital inpatient setting. The new codes will become effective on October 1, 2023, and are associated with higher payments compared to other Percutaneous Coronary Intervention (PCI) procedures. The new MS-DRGs aim to ensure access to the benefits of Shockwave IVL for patients with complex, calcified coronary artery disease.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.9%
Tags
none
Rhea-AI Summary
Shockwave Medical, Inc. will report financial results for the second quarter 2023 after market close on August 7, 2023. The company will host a conference call and present at the Canaccord Genuity 43rd Annual Growth Conference.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.34%
Tags
conferences earnings
-
Rhea-AI Summary
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.38%
Tags
none
-
Rhea-AI Summary
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.58%
Tags
management
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-6%
Tags
none
Shockwave Medical, Inc.

Nasdaq:SWAV

SWAV Rankings

SWAV Stock Data

12.39B
36.82M
1.27%
95.6%
5.43%
Surgical and Medical Instrument Manufacturing
Manufacturing
Link
United States of America
SANTA CLARA

About SWAV

shockwave medical is revolutionizing the interventional treatment of advanced cardiovascular disease by developing technology that targets calcified plaque. inspired by 30-years of safety and efficacy in kidney stone treatment, our lithoplasty® family of catheters delivers localized lithotripsy at the site of cardiovascular calcium that enables gentle balloon dilatation of calcified, stenotic arteries. lithoplasty devices use sonic pressure waves to preferentially impact hard tissue, disrupting calcium, while leaving soft tissue undisturbed. an integrated balloon catheter then dilates the calcified lesion at low-pressure, restoring blood flow. in peripheral vascular clinical study of moderate and severely calcified lesions in 95 patients, lithoplasty technology demonstrated safety and consistent procedure success with low procedural complications. the technology is inherently familiar, easy to use, operates with just the push of a button, and works with existing cardiovascular treatmen